Form 4: BioMarin CEO Hardy Reports Tax-Related Stock Disposition

BioMarin Pharmaceutical Inc.'s CEO, Alexander Hardy, reported a disposition of 4,252 common shares to cover tax liabilities related to a vesting event.

Summary

• Alexander Hardy, Chief Executive Officer and Director of BioMarin Pharmaceutical Inc. (BMRN), reported a transaction involving company common stock.
• On March 17, 2026, 4,252 shares of BioMarin common stock were disposed of.
• This disposition was coded 'F', indicating that the shares were withheld or delivered to satisfy tax obligations incident to the receipt, exercise, or vesting of a security.
• The shares were valued at $56.05 per share for the purpose of this tax-related transaction.
• Following this transaction, Alexander Hardy beneficially owns 214,635 shares of BioMarin common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, representing a standard compliance filing for an executive's tax-related share disposition rather than a discretionary investment decision.

Positives

• The transaction is a routine tax-related disposition of shares, not a discretionary sale, which is a common occurrence for executives receiving equity compensation.

Negatives

• The transaction is a routine tax-related disposition of shares, not a discretionary sale, and does not indicate any negative sentiment towards the company.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that tax-related dispositions of shares are common for executives receiving equity compensation, particularly after vesting events. This transaction is a routine compliance disclosure and does not indicate a change in investment sentiment or company strategy.

Comparison to Industry Standards

• This type of transaction (disposition for tax withholding) is standard practice across industries for executives receiving equity compensation.
• It is not comparable to discretionary sales or purchases that might reflect a view on company performance or valuation.

Stakeholder Impact

• This routine tax-related transaction has no direct impact on shareholders, employees, customers, suppliers, or creditors, as it is a compliance event related to executive compensation.

Key Dates

Recommendation

The filing details a routine tax-related disposition of shares by the CEO, which is a common occurrence for executives receiving equity compensation. It does not reflect a discretionary sale or purchase based on the company's performance or outlook, and therefore, does not provide new information to warrant a change in investment recommendation.

Keywords

BioMarin Pharmaceutical, BMRN, Alexander Hardy, Insider Transaction, Form 4, CEO Stock, Tax Withholding, Equity Compensation